About this trial
To determine whether regulating the gut microbiota can contribute to the eradication of refractory H. pylori infection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Ages 18-70
2. Hp infection treatment failed ≥4 times with guidelines-recommended therapies
3. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp.
Disqualifiers
1. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment;
2. Pregnant or lactating women;
3. Those who are allergic to the investigational drugs used in this test or have contraindications;
4. Participated in other drug trials within 3 months before the treatment of this trial;
Trial design
Single group
Treatments tested in this trial
transanal fecal bacteria transplant
Biological/VaccineReceived transanal fecal bacteria transplant
Treatment groups
Trial outcomes
Primary outcomes
Whether Hp is successfully eradicated
The successful eradication of Hp was determined by 13C urea breath test, immunohistochemical staining of Hp and Hp culture.test, immunohistochemical staining of gastric mucosa and Hp culture
Sponsors and contacts
Click on the lead sponsor to view all of their trials.